Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Severe Covid-19
David Berlin, Roy M. Gulick, Fernando J. Martínez
New England Journal of Medicine (2020) Vol. 383, Iss. 25, pp. 2451-2460
Closed Access | Times Cited: 1390

Showing 1-25 of 1390 citing articles:

Features, Evaluation and Treatment Coronavirus (COVID-19)
Marco Cascella, Michael Rajnik, Arturo Cuomo, et al.
StatPearls (2020)
Closed Access | Times Cited: 2796
Genomewide Association Study of Severe Covid-19 with Respiratory Failure
David Ellinghaus, Frauke Degenhardt, Luís Bujanda, et al.
New England Journal of Medicine (2020) Vol. 383, Iss. 16, pp. 1522-1534
Open Access | Times Cited: 2007
Considering how biological sex impacts immune responses and COVID-19 outcomes
Eileen P. Scully, Jenna Haverfield, Rebecca L. Ursin, et al.
Nature reviews. Immunology (2020) Vol. 20, Iss. 7, pp. 442-447
Open Access | Times Cited: 884
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19
Robert Gottlieb, Ajay Nirula, Peter Chen, et al.
JAMA (2021) Vol. 325, Iss. 7, pp. 632-632
Open Access | Times Cited: 884
Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19
Aldo Bonaventura, Alessandra Vecchiè, Lorenzo Dagna, et al.
Nature reviews. Immunology (2021) Vol. 21, Iss. 5, pp. 319-329
Open Access | Times Cited: 785
SARS-CoV-2 pathogenesis
Mart M. Lamers, Bart L. Haagmans
Nature Reviews Microbiology (2022) Vol. 20, Iss. 5, pp. 270-284
Open Access | Times Cited: 685
Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia
Carlo Salvarani, Giovanni Dolci, Marco Massari, et al.
JAMA Internal Medicine (2020) Vol. 181, Iss. 1, pp. 24-24
Open Access | Times Cited: 663
COVID-19 and the human innate immune system
Joachim L. Schultze, Anna C. Aschenbrenner
Cell (2021) Vol. 184, Iss. 7, pp. 1671-1692
Open Access | Times Cited: 661
Swarm Learning for decentralized and confidential clinical machine learning
Stefanie Warnat‐Herresthal, Hartmut Schultze, Krishnaprasad Lingadahalli Shastry, et al.
Nature (2021) Vol. 594, Iss. 7862, pp. 265-270
Open Access | Times Cited: 593
The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications
James D. McFadyen, Hannah Stevens, Karlheinz Peter
Circulation Research (2020) Vol. 127, Iss. 4, pp. 571-587
Open Access | Times Cited: 562
Autophagy in inflammation, infection, and immunometabolism
Vojo Deretić
Immunity (2021) Vol. 54, Iss. 3, pp. 437-453
Open Access | Times Cited: 548
Mechanism and inhibition of the papain‐like protease, PLpro, of SARS‐CoV‐2
Theresa Klemm, Gregor Ebert, Dale J. Calleja, et al.
The EMBO Journal (2020) Vol. 39, Iss. 18
Open Access | Times Cited: 428
Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Bin Zhang, Shuyi Liu, Tan Tan, et al.
CHEST Journal (2020) Vol. 158, Iss. 1, pp. e9-e13
Open Access | Times Cited: 427
Role of favipiravir in the treatment of COVID-19
Shashank Joshi, Jalil Parkar, Abdul Samad Ansari, et al.
International Journal of Infectious Diseases (2020) Vol. 102, pp. 501-508
Open Access | Times Cited: 422
Obesity in patients with COVID-19: a systematic review and meta-analysis
Yi Huang, Yao Lu, Yan‐Mei Huang, et al.
Metabolism (2020) Vol. 113, pp. 154378-154378
Open Access | Times Cited: 416
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
Michael Dougan, Ajay Nirula, Masoud Azizad, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 15, pp. 1382-1392
Open Access | Times Cited: 405
Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis
Ainsley Ryan Yan Bin Lee, Shi Yin Wong, Louis Yi Ann Chai, et al.
BMJ (2022), pp. e068632-e068632
Open Access | Times Cited: 390
COVID-19 pandemic—a focused review for clinicians
Müge Çevik, Connor G. G. Bamford, Antonia Ho
Clinical Microbiology and Infection (2020) Vol. 26, Iss. 7, pp. 842-847
Open Access | Times Cited: 388
Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial
Giacomo Lanzoni, Elina Linetsky, Diego Correa, et al.
Stem Cells Translational Medicine (2021) Vol. 10, Iss. 5, pp. 660-673
Open Access | Times Cited: 338
COVID-19 and liver disease: mechanistic and clinical perspectives
Thomas Marjot, Gwilym J. Webb, A. Sidney Barritt, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 5, pp. 348-364
Open Access | Times Cited: 334
Inflammasome activation at the crux of severe COVID-19
Setu M. Vora, Judy Lieberman, Hao Wu
Nature reviews. Immunology (2021) Vol. 21, Iss. 11, pp. 694-703
Open Access | Times Cited: 288
Development and Validation of the Quick COVID-19 Severity Index: A Prognostic Tool for Early Clinical Decompensation
Adrian D. Haimovich, Neal G. Ravindra, Stoytcho Stoytchev, et al.
Annals of Emergency Medicine (2020) Vol. 76, Iss. 4, pp. 442-453
Open Access | Times Cited: 282
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials
Cathrine Axfors, Andreas M. Schmitt, Perrine Janiaud, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 272
Virus-induced senescence is a driver and therapeutic target in COVID-19
Soyoung Lee, Yong Yu, Jakob Trimpert, et al.
Nature (2021) Vol. 599, Iss. 7884, pp. 283-289
Open Access | Times Cited: 268
Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID)
Anna Cristina Bertoldi Lemos, Douglas Alexandre do Espírito Santo, Maísa Cabetti Salvetti, et al.
Thrombosis Research (2020) Vol. 196, pp. 359-366
Open Access | Times Cited: 258
Page 1 - Next Page

Scroll to top